



PRESS RELEASE
07 February 2025 10:00:00 CET

Invitation to audiocast for Devyser's Q4 report 2024

On Tuesday February 13 at 13:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2024 report (which will have been published earlier on February 13 at 10:00 CET).

The presentation will be held in English.

If you wish to participate via webcast please use the link below.

<https://devyser-diagnostics.events.inderes.com/q4-report-2024/register>

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.inderes.com/teleconference/?id=5008325>

Speakers: Interim CEO Fredrik Dahl, CFO Sabina Berlin and CCO Theis Kipling

For more information, please contact:

Fredrik Dahl, interim CEO

Email: ir@devyser.com

Telephone: +46 8 562 158 50

Sabina Berlin, CFO

Email: ir@devyser.com

Telephone: +46 8 562 158 50



PRESS RELEASE

07 February 2025 10:00:00 CET

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.